Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rink TJ | Stimulus-response coupling mechanisms in human platelets. | 1986 | Agents Actions Suppl. | pmid:3028101 |
| Baroggi N et al. | Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. | 1986 | Agents Actions Suppl. | pmid:3028108 |
| Bertrand C et al. | Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. | 1990 | Agents Actions Suppl. | pmid:2080755 |
| Tsunoda H et al. | Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. | 1990 | Agents Actions Suppl. | pmid:2080757 |
| Sakuma Y et al. | Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. | 1990 | Agents Actions Suppl. | pmid:2080758 |
| Rihoux JP | The inhibiting effect of cetirizine 2 HC1 on eosinophil migration and its link to H1 blockade. | 1991 | Agents Actions Suppl. | pmid:1675836 |
| König W et al. | On the biological role of lipid chemotactic factors. | 1983 | Agents Actions Suppl. | pmid:6404145 |
| Kurosawa M | Effect of platelet activating factor on histamine release from rat mast cells. | 1987 | Agents Actions Suppl. | pmid:2445185 |
| Goldie RG et al. | PAF receptors in guinea-pig and human lung. | 1990 | Agents Actions Suppl. | pmid:1964365 |
| Parnham MJ et al. | Regulation of the oxidative burst of macrophages by lipid mediators. | 1984 | Agents Actions Suppl. | pmid:6433680 |
| Schrör K and Felsch A | Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. | 1992 | Agents Actions Suppl. | pmid:1334351 |
| Alabaster VA et al. | UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. | 1991 | Agents Actions Suppl. | pmid:1793066 |
| Heuer HO | The effects of hetrazepine PAF antagonists in preclinical models of asthma. | 1991 | Agents Actions Suppl. | pmid:1793067 |
| Mazzoni L et al. | Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. | 1991 | Agents Actions Suppl. | pmid:1793069 |
| Soloviev A and Braquet P | The similarity in action of hypoxia and platelet-activating factor on smooth muscle cells of coronary arteries: possible explanation for hypoxic coronary spasm development. | 1995 | Agents Actions Suppl. | pmid:7717190 |
| Billah MM et al. | Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. | 1991 | Agents Actions Suppl. | pmid:1793070 |
| Saeed SA et al. | Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. | 1991 | Agents Actions Suppl. | pmid:1793071 |
| Anderson GP and Fennessy MR | Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. | 1988 | Agents Actions Suppl. | pmid:3140616 |
| Page CP et al. | Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. | 1988 | Agents Actions Suppl. | pmid:3051932 |
| Muirhead EE | Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. | 1987 | Agents Actions Suppl. | pmid:3324720 |
| Mustard JF et al. | Platelet activation--an overview. | 1987 | Agents Actions Suppl. | pmid:3314414 |
| Page CP and Spina D | The therapeutic relevance of PAF antagonists. | 1989 | Agents Actions Suppl. | pmid:2683635 |
| Page CP and Robertson DN | Properties of PAF relevant to asthma. | 1987 | Agents Actions Suppl. | pmid:3314416 |
| Morley J | PAF and airway hyperreactivity; prospects for novel prophylactic anti-asthma drugs. | 1987 | Agents Actions Suppl. | pmid:3314417 |
| Braquet P et al. | The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021. | 1987 | Agents Actions Suppl. | pmid:3314418 |
| Mest HJ et al. | Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 | Agents Actions Suppl. | pmid:1632298 |
| Vargaftig BB | Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. | 1983 | Agents Actions Suppl. | pmid:6575594 |
| Koltai M and Braquet PG | Involvement of PAF in atherogenesis. Brief review. | 1992 | Agents Actions Suppl. | pmid:1632308 |
| Page CP et al. | PAF-acether: a putative mediator of asthma and inflammation. | 1983 | Agents Actions Suppl. | pmid:6575595 |
| Morley J et al. | Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. | 1988 | Agents Actions Suppl. | pmid:3262989 |
| Subissi A and Criscuoli M | Effects of LG 30435 on different platelet activating factor-induced responses. | 1988 | Agents Actions Suppl. | pmid:3262990 |
| Heuer H and Casals-Stenzel J | Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. | 1988 | Agents Actions Suppl. | pmid:3262991 |
| Hartung HP et al. | Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). | 1982 | Agents Actions Suppl. | pmid:6960648 |
| McMillan RM and Carter GW | Design and development of drugs. | 1991 | Agents Actions Suppl. | pmid:1664186 |
| Bult H et al. | Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. | 1984 | Agents Actions Suppl. | pmid:6382974 |
| Stenzel H et al. | Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. | 1987 | Agents Actions Suppl. | pmid:2823582 |
| O'Flaherty JT and Wykle RL | Metabolic origin and fate of platelet-activating factor. | 1987 | Agents Actions Suppl. | pmid:2823583 |
| Etienne A et al. | Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. | 1986 | Agents Actions Suppl. | pmid:3468781 |
| PAF, platelets and asthma. Proceedings of a meeting. September 7-9, 1986. | 1987 | Agents Actions Suppl. | pmid:3478993 | |
| Menz G et al. | Lack of PAF release in extrinsic asthma. | 1987 | Agents Actions Suppl. | pmid:3478995 |
| Szczeklik A et al. | Bleeding time and PAF-acether-induced platelet aggregation in atopy. | 1987 | Agents Actions Suppl. | pmid:3478996 |
| Schmitz-Schumann M et al. | Evidence of PAF release and platelet activation in analgesics-asthma-syndrome. | 1987 | Agents Actions Suppl. | pmid:3478999 |
| Guinot P et al. | Effects of BN 52063 on PAF-acether induced weal and flare in man. | 1987 | Agents Actions Suppl. | pmid:3479000 |
| Lang M et al. | Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. | 1987 | Agents Actions Suppl. | pmid:3479001 |
| Codde JP et al. | Effects of altered prostanoid and lyso-PAF synthesis by marine oil diets on blood pressure of salt loaded spontaneously hypertensive rats. | 1987 | Agents Actions Suppl. | pmid:3481207 |
| Chini M et al. | Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. | 2012 | AIDS Res. Hum. Retroviruses | pmid:22050695 |
| Lima RG et al. | Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. | 2006 | AIDS Res. Hum. Retroviruses | pmid:16910832 |
| Tsoupras AB et al. | Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? | 2008 | AIDS Res. Hum. Retroviruses | pmid:18620493 |
| Kelesidis T et al. | The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. | AIDS Rev | pmid:26616844 | |
| Greenberg SS et al. | Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. | 1996 | Alcohol. Clin. Exp. Res. | pmid:8904980 |